These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32356926)

  • 1. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.
    Rothlin RP; Vetulli HM; Duarte M; Pelorosso FG
    Drug Dev Res; 2020 Nov; 81(7):768-770. PubMed ID: 32356926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning of histamine H
    Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
    Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
    Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
    Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
    Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis.
    Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF
    Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
    Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
    Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19.
    Batchu SN; Kaur H; Yerra VG; Advani SL; Kabir MG; Liu Y; Klein T; Advani A
    Diabetes; 2021 Mar; 70(3):759-771. PubMed ID: 33310740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19.
    Pedrosa MA; Valenzuela R; Garrido-Gil P; Labandeira CM; Navarro G; Franco R; Labandeira-Garcia JL; Rodriguez-Perez AI
    Clin Sci (Lond); 2021 Feb; 135(3):465-481. PubMed ID: 33479758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury.
    Yamaguchi T; Hoshizaki M; Minato T; Nirasawa S; Asaka MN; Niiyama M; Imai M; Uda A; Chan JF; Takahashi S; An J; Saku A; Nukiwa R; Utsumi D; Kiso M; Yasuhara A; Poon VK; Chan CC; Fujino Y; Motoyama S; Nagata S; Penninger JM; Kamada H; Yuen KY; Kamitani W; Maeda K; Kawaoka Y; Yasutomi Y; Imai Y; Kuba K
    Nat Commun; 2021 Nov; 12(1):6791. PubMed ID: 34815389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.
    Parit R; Jayavel S
    Eur J Pharmacol; 2021 Apr; 896():173899. PubMed ID: 33508281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
    Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H
    FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
    Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
    Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elovanoids downregulate SARS-CoV-2 cell-entry, canonical mediators and enhance protective signaling in human alveolar cells.
    Calandria JM; Bhattacharjee S; Maness NJ; Kautzmann MI; Asatryan A; Gordon WC; Do KV; Jun B; Mukherjee PK; Petasis NA; Bazan NG
    Sci Rep; 2021 Jun; 11(1):12324. PubMed ID: 34112906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble ACE2 as a potential therapy for COVID-19.
    Krishnamurthy S; Lockey RF; Kolliputi N
    Am J Physiol Cell Physiol; 2021 Mar; 320(3):C279-C281. PubMed ID: 33502950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system.
    Rysz S; Al-Saadi J; Sjöström A; Farm M; Campoccia Jalde F; Plattén M; Eriksson H; Klein M; Vargas-Paris R; Nyrén S; Abdula G; Ouellette R; Granberg T; Jonsson Fagerlund M; Lundberg J
    Nat Commun; 2021 Apr; 12(1):2417. PubMed ID: 33893295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.